Literature DB >> 30111973

Real-world patient- and caregiver-reported outcomes in advanced breast cancer.

V Lambert-Obry1, A Gouault-Laliberté1, A Castonguay1, G Zanotti2, T Tran3, M Mates4, J Lemieux5, P Chabot6, C Prady7, F Couture8, J Lachaine1.   

Abstract

Background: Advanced breast cancer (abc) represents a substantial burden for patients and caregivers. In the present study, we aimed to estimate quality of life (qol), utility, productivity loss, pain, health care resource utilization, and costs for patients with abc, and qol, utility, and productivity loss for their caregivers.
Methods: This multicentre prospective non-interventional study was conducted in Canada. Eligible participants were postmenopausal women with estrogen receptor-positive, her2-negative unresectable abc and their caregivers. Validated questionnaires were used to measure qol, utility, productivity loss, and pain. Patients and caregivers were classified into 4 health states typically used in oncology economic modelling: first-line progression-free (1l-pf), first-line progressive disease (1l-pd), second- or subsequent-line progression-free (≥2l-pf), and second- or subsequent-line progressive disease (≥2l-pd).
Results: Most patients and caregivers accepted to participate, with total recruitment of 202 patients and 78 caregivers. Compared with patients in pf, patients in pd had lower mean qol scores (52.9 ± 29.9 for 1l-pd vs. 68.2 ± 23.2 for 1l-pf, and 54.0 ± 23.6 for ≥2l-pd vs. 66.0 ± 22.1 for ≥2l-pf), lower mean utility values (0.64 ± 0.22 for 1l-pd vs. 0.73 ± 0.20 for 1l-pf, and 0.65 ± 0.25 for ≥2l-pd vs. 0.74 ± 0.18 for ≥2l-pf), and greater productivity loss (39.4 ± 27.7 for 1l-pd vs. 27.5 ± 30.1 for 1l-pf, and 37.6 ± 29.2 for ≥2l-pd vs. 32.0 ± 29.0 for ≥2l-pf). Compared with caregivers of patients in pf, caregivers of patients in pd had lower qol scores and utility values, and greater productivity loss. Conclusions: Study results indicate that, for patients and caregivers, pd health states are associated with a deterioration of qol and utility and a decrease in productivity in both 1l and ≥2l.

Entities:  

Keywords:  Real-world evidence; advanced breast cancer; caregivers; health care resource utilization; patient-reported outcomes; productivity losses; quality of life; utility

Mesh:

Year:  2018        PMID: 30111973      PMCID: PMC6092048          DOI: 10.3747/co.25.3765

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  12 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  The validity and reproducibility of a work productivity and activity impairment instrument.

Authors:  M C Reilly; A S Zbrozek; E M Dukes
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 3.  Self-reported utilization of health care services: improving measurement and accuracy.

Authors:  Aman Bhandari; Todd Wagner
Journal:  Med Care Res Rev       Date:  2006-04       Impact factor: 3.929

4.  Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.

Authors:  Louis P Garrison; Peter J Neumann; Pennifer Erickson; Deborah Marshall; C Daniel Mullins
Journal:  Value Health       Date:  2007 Sep-Oct       Impact factor: 5.725

5.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  F Cardoso; N Harbeck; L Fallowfield; S Kyriakides; E Senkus
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

6.  The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer.

Authors:  Patricia Minaya; Karine Baumstarck; Julie Berbis; Anthony Goncalves; Fabrice Barlesi; Gérard Michel; Sébastien Salas; Olivier Chinot; Jean-Jacques Grob; Jean François Seitz; Franck Bladou; Audrey Clement; Julien Mancini; Marie-Claude Simeoni; Pascal Auquier
Journal:  Eur J Cancer       Date:  2011-10-25       Impact factor: 9.162

7.  Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Ann H Partridge; R Bryan Rumble; Lisa A Carey; Steven E Come; Nancy E Davidson; Angelo Di Leo; Julie Gralow; Gabriel N Hortobagyi; Beverly Moy; Douglas Yee; Shelley B Brundage; Michael A Danso; Maggie Wilcox; Ian E Smith
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

Review 8.  Pain assessment: global use of the Brief Pain Inventory.

Authors:  C S Cleeland; K M Ryan
Journal:  Ann Acad Med Singapore       Date:  1994-03       Impact factor: 2.473

9.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

10.  3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Authors:  F Cardoso; A Costa; E Senkus; M Aapro; F André; C H Barrios; J Bergh; G Bhattacharyya; L Biganzoli; M J Cardoso; L Carey; D Corneliussen-James; G Curigliano; V Dieras; N El Saghir; A Eniu; L Fallowfield; D Fenech; P Francis; K Gelmon; A Gennari; N Harbeck; C Hudis; B Kaufman; I Krop; M Mayer; H Meijer; S Mertz; S Ohno; O Pagani; E Papadopoulos; F Peccatori; F Penault-Llorca; M J Piccart; J Y Pierga; H Rugo; L Shockney; G Sledge; S Swain; C Thomssen; A Tutt; D Vorobiof; B Xu; L Norton; E Winer
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

View more
  4 in total

Review 1.  Living with Advanced Breast Cancer: A Descriptive Analysis of Survivorship Strategies.

Authors:  Michael Grimm; Lindsey Radcliff; Mariann Giles; Ryan Nash; Erin Holley; Shannon Panda; Lynne Brophy; Nicole Williams; Mathew Cherian; Daniel Stover; Margaret E Gatti-Mays; Robert Wesolowski; Sagar Sardesai; Preeti Sudheendra; Raquel Reinbolt; Bhuvaneswari Ramaswamy; Ashley Pariser
Journal:  J Clin Med       Date:  2022-07-10       Impact factor: 4.964

2.  Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.

Authors:  Alison Davie; Gebra Cuyun Carter; Alex Rider; James Pike; Katie Lewis; Abigail Bailey; Gregory L Price; Francois Ringeisen; Xavier Pivot
Journal:  BMC Cancer       Date:  2020-09-07       Impact factor: 4.430

3.  Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry.

Authors:  Anouk K M Claessens; Bram L T Ramaekers; Dorien J A Lobbezoo; Roel J W van Kampen; Maaike de Boer; Agnes J van de Wouw; M Wouter Dercksen; Sandra M E Geurts; Manuela A Joore; Vivianne C G Tjan-Heijnen
Journal:  Qual Life Res       Date:  2020-08-20       Impact factor: 4.147

4.  Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.

Authors:  Lydia Loke; Soo-Chin Lee; Fiona Pearce; Kwong Ng; Mohamed Ismail Abdul Aziz
Journal:  Cancer Rep (Hoboken)       Date:  2020-10-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.